Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Last trade$26.22
Day change-$0.155 (-0.59%)
Day range$25.74 – $27.08
Volume82,414
Market cap$591M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$590.72M
Price / earnings
24.8×
Price / book
2.6×
Price / sales
1.66×
EV / sales
1.45×
EV / EBITDA
12.18×
Profitability
Earnings per share
$1.06
Return on assets
8.18%
Return on equity
10.48%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.51×
Quick ratio
3.18×
Cash ratio
1.58×
Cash flow
Price / cash flow
18.35×
Price / free cash flow
20.35×
Free cash flow
$29.02M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TCMD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$91.86M
$85.7M
$75.27M
$103.59M
$85.76M
$78.91M
$61.27M
$85.59M
Cost of revenue
$21.37M
$20.35M
$17.65M
$22.59M
$20.75M
$20.11M
$15.92M
$21.22M
Gross profit
$70.49M
$65.35M
$57.61M
$81.01M
$65M
$58.79M
$45.35M
$64.37M
Selling, general and administrative
$57.7M
$55.37M
$55.78M
$59.1M
$51.25M
$52.07M
$47.51M
$49.18M
Research and development
$2.51M
$2.5M
$2.78M
$2.53M
$2.19M
$2.02M
$1.74M
$2.04M
Total operating expenses
$60.9M
$58.52M
$59.15M
$62.23M
$54.04M
$54.71M
$49.89M
$51.85M
Operating income
$9.59M
$6.83M
-$1.53M
$18.78M
$10.96M
$4.08M
-$4.54M
$12.52M
Interest expense
-$20K
-$19K
-$28K
-$11K
-$193K
-$410K
-$424K
-$471K
Income before taxes
$10.13M
$7.37M
-$896K
$19.45M
$11.44M
$4.52M
-$4.07M
$12.99M
Income taxes
$2.97M
-$417K
$867K
$8.82M
$3.23M
$1.31M
-$1.1M
$3.28M
Net income
$7.16M
$7.79M
-$1.76M
$10.63M
$8.21M
$3.22M
-$2.97M
$9.72M
Net income attributable to common shareholders
$7.16M
$7.79M
-$1.76M
$10.63M
$8.21M
$3.22M
-$2.97M
$9.72M
EBITDA
$11.36M
$9.29M
$701K
$20.99M
$12.6M
$6.36M
-$2.18M
$14.86M
Basic earnings per share
$0.32
$0.34
-$0.08
$0.48
$0.37
$0.14
-$0.13
$0.40
Diluted earnings per share
$0.31
$0.34
-$0.08
$0.45
$0.36
$0.14
-$0.13
$0.40
Recent news
Company coverage with links to the original publishers.
Intuitive Surgical agreed to a $450 million no-fault settlement over third-party da Vinci servicing and instrument remanufacturing. While the settlement reduced Q3 GAAP EPS to $1.49, adjusted EPS rose 25% year-over-year to $3.00. Revenues grew 22% to $3 billion with procedures up 15%, demonstrating strong underlying operational momentum despite the litigation charge.
Tactile Systems Technology (TCMD) has gained 11.7% over the past four weeks and Wall Street analysts project a potential 52% upside with a mean price target of $37.67. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.
Tactile Systems raised full-year adjusted EBITDA guidance to $50-52 million, driven by 13% year-over-year growth in lymphedema product revenue to $81.8 million and operational improvements that reduced medical record review times by 50%. The company is absorbing temporary inventory delays in its airway clearance business through margin expansion and controlled spending, while positioning itself for sustained growth through expanded sales teams and AI-enabled order management systems.
Tactile Systems Technology (TCMD) beat EPS estimates with $0.31 per share versus consensus of $0.30, but missed revenue expectations at $91.86 million. The stock has underperformed the market by 20.6% year-to-date. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Instruments industry ranks in the top 42% of Zacks industries.
Tactile Systems Technology reported Q3 revenue growth of 7% to $91.9 million, but net income declined to $7.2 million from $8.2 million as operating expenses grew at the same pace as sales. While the core lymphedema business grew 13%, the smaller airway clearance line contracted 25% due to inventory adjustments from a product launch. The company maintained its 2026 revenue guidance but slightly raised profit forecasts, though Q4 adjusted EBITDA is expected to be 2-10% below last year.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.